In a study of symptomatic adults tested for SARS-CoV-2 at U.S. pharmacies since Sept. 14, bivalent COVID-19 vaccine boosters provided additional protection compared with previous vaccination with two or more monovalent doses, the Centers for Disease Control and Prevention reported today. The benefit of the bivalent booster increased with time since receipt of the last monovalent dose. 
 
In a separate study released today, adult COVID-19 patients with mild-to-moderate illness who received a prescription for Paxlovid had a 51% lower hospitalization rate than those who did not, CDC said. While the initial clinical trial for Paxlovid preceded the omicron variant’s predominance and included only unvaccinated patients, the new study included people with omicron infection and previous immunity. 

Related News Articles

Headline
Just in time for March Madness, AHA is offering for hospitals and health systems a social media toolkit that uses the wildly popular NCAA basketball tournament…
Headline
The Food and Drug Administration yesterday amended its emergency use authorization for Pfizer’s updated COVID-19 vaccine to allow children aged 6 months…
Headline
Completing the Moderna or Pfizer COVID-19 monovalent vaccine primary series protects children aged 3-5 and 3-4, respectively, against symptomatic SARS-CoV-2…
Headline
AHA is offering for hospitals and health systems a second social media toolkit for February with messages for promoting COVID-19 vaccination and boosters. The…
Headline
A new video from AHA and the Children’s Hospital Association is reminding the public how vaccines and boosters are safe, effective means for preventing…
Headline
In a new public service announcement, leaders of the AHA, American Medical Association and American Nurses Association encourage the public to get vaccinated…